Trastuzumab-Induced Tumor Microenvironment Changes in Early HER2+Breast Cancer

被引：0
|
作者：
Kennedy, Laura C.
Alvarez, Rebeca
Dintzis, Suzanne
Gadi, Vijayakrishna K.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P2-23-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-23-05
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Safety of trastuzumab in women with HER2+breast cancer.
    Nowsheen, Somaira
    Aziz, Khaled
    Park, Jae Yoon
    Villarraga, Hector R.
    Herrmann, Joerg
    Ruddy, Kathryn Jean
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [12] Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+breast cancer
    Dackus, Gwen M. H. E.
    Jozwiak, Katarzyna
    van der Wall, Elsken
    van Diest, Paul J.
    Hauptmann, Michael
    Siesling, Sabine
    Sonke, Gabe S.
    Linn, Sabine C.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (03) : 817 - 830
  • [13] Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids
    Rodriguez, Cristina E.
    Reidel, Sara I.
    Bal de Kier Joffe, Elisa D.
    Jasnis, Maria A.
    Fiszman, Gabriel L.
    PLOS ONE, 2015, 10 (09):
  • [14] The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
    Lin, Mengmeng
    Xiong, Weiping
    Wang, Shiyuan
    Li, Yingying
    Hou, Chunying
    Li, Chunyu
    Li, Guohui
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 8
  • [15] Trastuzumab-induced cardiotoxicity in Uruguayan HER2-positive breast cancer patients.
    Schiavone, Andrea
    Diaz, Mariana
    Camejo, Natalia
    Reborido, Natalia
    Vazquez, Horacio
    Parma, Gabriel
    Vazquez, Alvaro
    Castillo, Cecilia
    Krygier, Gabriel David
    Delgado, Lucia Beatriz
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [16] Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+breast cancer cells
    Murad, Rabi
    Avanes, Arabo
    Ma, Xinyi
    Geng, Shuhui
    Mortazavi, Ali
    Momand, Jamil
    GENE, 2021, 799
  • [17] Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+breast cancer
    Magali Mondaca, Joselina
    Castro Guijarro, Ana Carla
    Ines Flamini, Marina
    Matias Sanchez, Angel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (02) : 363 - 377
  • [18] A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer
    Ben Kridis, Wala
    Sghaier, Syrine
    Charfeddine, Salma
    Toumi, Nabil
    Daoud, Jamel
    Kammoun, Samir
    Khanfir, Afef
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (07): : 510 - 516
  • [19] Adjuvant trastuzumab and vinorelbine (TV) for early-stage HER2+breast cancer.
    McLaughlin, Shannon
    Nakajima, Erika
    Isakoff, Steven J.
    Shin, Jennifer
    Moy, Beverly
    Bardia, Aditya
    Kuter, Irene
    Spring, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [20] Pruritus related to trastuzumab and pertuzumab in HER2+breast cancer patients
    Gu, Stephanie
    Dusza, Stephen
    Quigley, Elizabeth
    Haliasos, Helen
    Markova, Alina
    Marchetti, Michael
    Moy, Andrea P.
    Dang, Chau
    Modi, Shanu
    Lake, Diana
    Noor, Sarah
    Lacouture, Mario E.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 271 - 280
12345